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Fatal Rhabdomyolysis in a Patient with Liver Cirrhosis after 
Switching from Simvastatin to Fluvastatin
HMG-CoA reductase inhibitors (statins) are widely used to treat hypercholesterolemia. 
Among the adverse effects associated with these drugs are statin-associated myopathies, 
ranging from asymptomatic elevation of serum creatine kinase to fatal rhabdomyolysis. 
Fluvastatin-induced fatal rhabdomyolysis has not been previously reported. We describe 
here a patient with liver cirrhosis who experienced fluvastatin-induced fatal 
rhabdomyolysis. This patient had been treated with simvastatin (20 mg/day) for coronary 
artery disease and was switched to fluvastatin (20 mg/day) 10 days before admission. He 
was also taking aspirin, betaxolol, candesartan, lactulose, and entecavir. Rhabdomyolysis 
was complicated and continued to progress. He was treated with massive hydration, urine 
alkalization, intravenous furosemide, and continuous renal replacement therapy for acute 
renal failure, but eventually died due to rhabdomyolysis complicated by hepatic failure. In 
conclusion, fluvastatin should be used with caution in patients with liver cirrhosis, 
especially with other medications metabolized with CYP2C9.
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Statins are used to lower serum cholesterol concentrations in 
the primary and secondary prevention of cardiovascular disease 
(1). In randomized trials, the use of statins has demonstrated 
30% reductions in atherosclerotic end points without serious 
morbidity. The pleiotropic effects of statins, indirectly related to 
cholesterol-lowering activities (2), have also been assessed, mak-
ing these drugs more widely accepted in various clinical settings. 
  Fluvastatin, available as both fluvastatin sodium and fluvas-
tatin extended-release, is the first synthetic 3-hydroxy-3-meth-
ylglutaryl coenzyme A reductase inhibitor. Because fluvastatin 
is well tolerated and lacks clinically significant drug-drug inter-
actions, it is regarded as one of the safest statins, especially in 
patients receiving multiple medications (3). Even patients with 
renal disease, renal transplantation recipients and patients who 
have undergone PCI can be safely treated with fluvastatin (4).
  The most significant adverse effect associated with statins is 
muscle toxicity. This includes a broad clinical spectrum of dis-
orders, from mild and non-specific muscle aches or weakness, 
through asymptomatic and symptomatic elevation of serum 
creatine kinase levels, to life-threatening rhabdomyolysis. To 
date, few cases of fatal rhabdomyolysis associated with the use 
of statins have been reported; these include 19 patients taking 
lovastatin, 3 taking pravastatin, 14 taking simvastatin, 6 taking 
atorvastatin, and 31 taking cerivastatin, the latter which was with-
drawn worldwide (5). There have been no reports to date of fatal 
rhabdomyolysis associated with the use of fluvastatin. We re-
port a case of fluvastatin-induced fatal rhabdomyolysis in a pa-
tient with liver cirrhosis; this patient had been switched from 
simvastatin to fluvastatin 10 days earlier and died due to severe 
rhabdomyolysis complicated by hepatic failure.
CASE DESCRIPTION
A 56-yr-old man with liver cirrhosis caused by the hepatitis B 
virus visited our hospital on December 30, 2008 for evaluation 
of weakness in his lower legs of 1-week duration. He first expe-
rienced discomfort and myalgia in his lower legs, which wors-
ened over time and made him unable to walk. He had under-
gone a percutaneous coronary intervention 10 yr previously at 
the local hospital and had taken simvastatin (20 mg/day) regu-
larly since then. He was diagnosed with Child-Pugh C cirrhosis 
due to hepatitis B virus a year ago and followed-up at the same Baek SD, et al.  •  Fluvastatin-associated Rhabdomyolysis with Liver Cirrhosis
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hospital with stable liver function in a compensated state. Ten 
days before visiting our hospital, he was switched from simvas-
tatin to fluvastatin (20 mg/day) by his doctor, as the patient was 
concerned about his liver disease. In addition to fluvastatin (20 
mg/day), his medications included aspirin (100 mg/day), be-
taxolol (10 mg/day), candesartan (16 mg/day), lactulose (30 
mL/day), and entecavir (0.5 mg/day) without diuretics or fi-
brates. His medical history was significant for no alcohol use 
and 10 pack-years of smoking, but he had quit smoking 10 yr 
previously. 
  The patient’s blood pressure was 122/76 mmHg, his temper-
ature was 36.8°C, his pulse was 63 beats/min, weight was 98 kg, 
and his body mass index was 29.8 kg/m
2. He had mild tender-
ness of the lower extremities but all other assessments were un-
remarkable. Laboratory findings included sodium 125 mM/L, 
potassium 5.1 mM/L, chloride 97 mM/L, phosphorus 3.1 mg/
dL, CO2 24.4 mM/L, serum creatinine 1.0 mg/dL, blood urea 
nitrogen 21 mg/dL, glucose 176 mg/dL, calcium 8.3 mg/dL, 
phosphorus 3.1 mg/dL, aspartate transaminase 1,303 IU/L (nor-
mal < 40), alanine transaminase 354 IU/L (normal < 40), alka-
line phosphatase 145 IU/L (normal 40 to 120), total bilirubin 4.6 
mg/dL, direct bilirubin 1.4 mg/dL, protein 8.0 g/dL, albumin 2.7 
g/dL, and uric acid 3.5 mg/dL. His hematocrit was 38.5%, plate-
let count was 80,000/µL, and white blood cell count was 11,100/
µL, with 18.5% lymphocytes, 69.7% polymorphonuclear leuko-
cytes, 10.2% monocytes, 1.4% eosinophils, and 0.2% basophils. 
His prothrombin time (PT) was 1.78 INR (40.7%) and activated 
partial thromboplastin time (aPTT) was 36.5 seconds. His total 
serum creatine kinase (CK) was 36,804 IU/L (normal 50 to 250 
IU/L) and his CK-MB was 157.0 ng/mL (normal < 5 ng/mL). Thy-
roid function test was within normal limits. Urinalysis revealed 
no red or white blood cells, positive dipsticks for protein, occult 
blood, bilirubin and urobilinogen, but negative for glucose. A 
99mTc-diphosphonate scintigram bone scan showed increased 
uptake over all extremities and muscles of the thorax and abdo-
men (Fig. 1).
  The patient was diagnosed with fluvastatin-induced rhabdo-
myolysis. Treatment with fluvastatin, betaxolol and candesartan 
was discontinued, and he received massive hydration and urine 
alkalization. He was treated with intravenous sodium bicarbon-
ate (100 mEq in 1,000 mL of half-normal saline at a rate of up to 
500 mL/h or 50 mEq/h) titrated to a urine pH > 6.5. He was ad-
ministered a 20-80 mg dose of intravenous furosemide to main-
tain diuresis. The extent of rhabdomyolysis progressed despite 
supportive treatment. His CK concentration was increased to 
166,160 IU/L, and renal failure occurred. He underwent contin-
uous renal replacement therapy on day 7, but his renal function 
did not recover and hepatic function worsened, with PT pro-
longed to 3.8 INR (18%) and total bilirubin increased to 24.5 mg/ 
dL (Fig. 2). He died due to rhabdomyolysis complicated by he-
patic failure on day 15. Fig. 1. A 
99mTc-diphosphonate scintigram bone scan showed increased uptake over 
all extremities and muscles of the thorax and abdomen.
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Fig. 2. Changes in serum CK and 
PT concentrations during admis-
sion. CRRT, continous renal re-
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DISCUSSION
Fluvastatin is one of the statins shown to reduce the incidence 
of vascular events and slow the angiographically demonstrated 
progression of atherosclerotic disease (4). Since its approval in 
1993, fluvastatin has been administered for more than 21 mil-
lion patient-years worldwide. Among the statins, fluvastatin has 
been associated with the fewest cases of rhabdomyolysis. Al-
though there was a report of fatal rhabdomyolysis induced by 
fluvastatin-gemfibrozil combination therapy (6), to our knowl-
edge, fluvastatin alone has not been reported to induce fatal 
rhabdomyolysis.
  Our patient had both chronic liver disease and established 
coronary artery disease, making it difficult to choose the most 
appropriate type and dose of statin, or even whether to treat with 
statin. The benefits of statins in lowering cholesterol and prevent-
ing heart disease outweigh the potential risks of hepatotoxicity, 
even in patients with chronic liver disease (7). The National Lipid 
Association (NLA) expert liver panel has stated that patients with 
chronic liver disease, nonalcoholic fatty liver disease and non-
alcoholic steatohepatitis may safely receive statin therapy, sup-
porting no scientific evidence to contraindicate statin use in pa-
tients with compensated cirrhosis (8). Literature has also indi-
cated that use of statins in patients with hepatitis C infection and 
primary biliary cirrhosis is safe. Statins have not been shown to 
worsen the outcome in persons with chronically increased trans-
aminase levels due to hepatitis B or C viruses (9). However, the 
incidence of discontinuations from statins due to hepatotoxici-
ty was significantly higher in HBsAg-positive than in HBsAb-
negative patients with coronary heart disease (10). Statins are 
contraindicated in patients with active liver disease or unex-
plained, persistent increases in liver function tests.
  Except for cerivastatin, all statins have a very low systemic 
bioavailability owing to their extensive first-pass extraction by 
the liver. All statins, except for pravastatin, undergo microsomal 
metabolism by the cytochrome P450 (CYP) isoenzyme systems. 
Inhibition of CYP450 isoenzymes by concomitantly interacting 
drugs can lead to increased plasma concentrations of statins, 
resulting in myositis and rhabdomyolysis. Fibrates, warfarin, di-
goxin and mibefradil have been reported in patients with statin-
associated rhabdomyolysis (11). Advanced age, diabetes, chron-
ic renal insufficiency, and multiple medications are also associ-
ated with increased risks of statin-associated myopathy (9). Our 
patient, however, was not taking any drugs that interact with 
statins, nor was he ingesting alcohol. He did not have any other 
factors including hypokalemia, hypophosphatemia, hypo- or 
hyperthyroidism, and diuretics that could predispose him to 
the development of myopathy. No clinically important interac-
tions have been observed between statins and other drugs used 
in cardiovascular diseases, such as propranolol, angiotensin-con-
verting enzyme inhibitors, and thiazide diuretics (12).
  About half of all statins currently available in clinical practice 
are biotransformed in the liver, primarily by the CYP450 3A4 sys-
tem. Fluvastatin, unlike other statins, is metabolized primarily 
by the CYP2C9 enzyme in the liver, with CYP3A4 and CYP2C8 
contributing to a lesser extent, and is therefore less subject to in-
teractions than other statins (13). Thus, fluvastatin has a favor-
able adverse effect profile among the statins. As fluvastatin has 
the shortest elimination half-life of inactive metabolites among 
the statins and higher liver extraction, however, it results in high 
liver and peripheral tissue concentration, minimizing the sys-
temic burden, instead potentiating hepatocellular injury in se-
rious liver disease (6). In a population based cohort study (14), 
the highest risk of serious liver dysfunction among statins was 
associated with fluvastatin (hazard ratio 2.53, 95% confidence 
interval 1.84-3.47), which was significantly higher than that with 
simvastatin (hazard ratio 1.52, 95% confidence interval 1.38 to 
1.66). With regard to this, our patient with liver cirrhosis was sub-
ject to serious adverse effects.  
  Among his medications, betaxolol is metabolized by CYP1A2 
and CYP2D6 (15). Candesartan is primarily excreted as un-
changed drug (75%) in the urine and feces with a smaller pro-
portion (20%-25%) inactivated by CYP2C9. Entecavir and lactu-
lose are not substrates for and do not inhibit or induce CYP iso-
enzymes. However, the major enzymes involved in glucuroni-
dation and hydroxylation of NSAIDs are CYP2C9 (16). There-
fore, we could not exclude the possibility that CYP2C9 enzyme 
in our patient was partially saturated with candesartan and as-
pirin or he had genetic variants in CYP2C9, which we could not 
identify unfortunately. 
  Statin-associated myopathies are dose-dependent and com-
parable among the various statins. Simvastatin is more potent 
than fluvastatin in lowering cholesterol. At doses of 20 mg/d, 
simvastatin and fluvastatin can reduce low-density lipoprotein 
by 30%-40% and 10%-20%, respectively. Lipophilic statins, in-
cluding lovastatin, simvastatin, and cerivastatin, also have a great-
er potential for muscle toxicity than do hydrophilic statins in-
cluding fluvastatin, atorvastatin, and pravastatin owing to their 
enhanced ability to penetrate myocytes. In our patient, rhabdo-
myolysis occurred after switching from a high- to a low-potency 
statin. It could be preliminarily explained in addition from a re-
port that hepatic reactions associated with fluvastatin might be 
more common and more serious than those caused by other 
statins (17), especially in patients with hepatic dysfunction. In 
one third of severe hepatotoxicity associated with fluvastatin, it 
occurred after < 1 month of therapy. 
  Fluvastatin is an established treatment for hypercholesterol-
emia; its efficacy and safety have been documented in several 
clinical trials. Rhabdomyolysis associated with fluvastatin is very 
rare, with the adverse event reporting system of the U.S. Food 
and Drug Administration showing that only 1.7% of the incidents 
of statin-associated rhabdomyolysis were related to fluvastatin Baek SD, et al.  •  Fluvastatin-associated Rhabdomyolysis with Liver Cirrhosis
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administration. However, our findings indicate that fluvastatin 
should be used with caution in patients with liver cirrhosis, es-
pecially with other medications metabolized with CYP2C9.
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